ClearPoint Neuro, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Tables)

Stockholders’ Equity (Tables)

6 Months Ended

Jun. 30, 2022

The Company records share-based compensation expense on a straight-line basis over the related vesting period and recognizes forfeitures as they occur. The following table sets forth share-based compensation expense included in general and administrative expense in the condensed consolidated statements of operations:


Three Months Ended June 30,		Six Months Ended June 30,
(in thousands)		(in thousands)
2022	2021	2022	2021
$880	$247	$1,779	$567

Schedule of Stock Option Activity

Stock option activity under all of the Company’s plans during the six months ended June 30, 2022 is summarized below:


	Stock Options	Weighted-average Exercise price per share		Weighted-average Remaining Contractual Life (in years)	Intrinsic Value(1) (in thousands)
Outstanding at December 31, 2021	1,350,473	$	10.10
Granted	147,723	$	10.91
Exercised	(1,000)	$	2.60
Forfeited or expired	(75,723)	$	40.07
Outstanding at June 30, 2022	1,421,473	$	8.59	6.6	$	10,479


(1)			Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.

Schedule of Restricted Stock Awards Activity

Restricted Stock Activity

Restricted stock activity, which includes restricted stock awards ("RSA") and restricted stock unit awards ("RSU"), for the six months ended June 30, 2022 is summarized below:


	Restricted Stock	Weighted - Average Grant Date Fair Value
Outstanding at December 31, 2021	380,105	$	10.41
Granted	447,175	$	10.90
Vested	(32,107)	$	10.01
Forfeited	(22,991)	$	14.41
Outstanding at June 30, 2022	772,182	$	10.25

Schedule of Common Stock Warrant Activity

Common stock warrant activity for the six months ended June 30, 2022 is as follows:


	Warrant Shares	Weighted-average Exercise price per share		Intrinsic Value(1) (in thousands)
Outstanding at December 31, 2021	668,907	$	2.97
Exercised	(462,353)	$	2.20
Terminated	(170,000)	$	2.20
Outstanding at June 30, 2022	36,554	$	16.23	$	—


(1)			Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the warrant exercise price of in-the-money warrants.